Effects of Bifidobacterium lactis BB12 probiotic consumption on Streptococcus mutans levels: systematic review of randomized clinical trials
This systematic review reports a favorable association between BB12 consumption and reduced Streptococcus mutans counts, but provides no quantitative data, effect sizes, or 95% CIs to support a robust clinical conclusion.
| Outcome | Grade | Direction | Effect | Studies |
|---|---|---|---|---|
| Streptococcus mutans count | C | ▲ Favorable | not reported (qualitative association only; no SMD, RR, OR, MD or 95% CI available) | — |
Context
Streptococcus mutans is the primary bacterial pathogen in dental caries, a disease affecting 2.3 billion adults and 520 million children worldwide according to the WHO. Probiotics are under investigation as adjunct strategies to modulate oral microbiota. The absence of quantitative synthesis in this review severely limits its direct clinical utility.
What the study showed
The review reports an association between BB12 consumption and SM count reduction, but provides no absolute or relative numbers, no 95% CIs, no effect sizes (RR, OR, SMD, MD), and no meta-analysis. The available full text is limited to the abstract and introduction; numerical results from included RCTs were not accessible for analysis. The authors themselves acknowledge the need for larger-sample, longer-duration studies.
How it was done
Systematic review of RCTs searching PubMed, Scopus, EBSCO, and EMBASE for studies evaluating BB12 effects on SM in children and adults. Number of included studies, detailed eligibility criteria, risk-of-bias assessment tools, and data extraction protocols are not described in the available text. No meta-analysis was performed.
Effect magnitude
Not calculable: the text reports no effect size, 95% CI, or quantitative data from any included RCT. The claim of 'association with reduction' is qualitative and lacks verifiable numerical support.
Limitations
Available full text is limited to the abstract and introduction, preventing complete appraisal. No risk-of-bias tool is described (RoB 2 would be appropriate for RCTs; AMSTAR-2 for the review itself). Absence of meta-analysis, quantitative synthesis, and individual study data severely undermines the validity of conclusions. Small samples and short duration are acknowledged by the authors. Heterogeneity across BB12 formulations is not quantified.
In clinical practice
Current evidence does not support a specific clinical recommendation for BB12 use as an SM-reduction strategy. Clinicians should not alter established preventive protocols based on this review alone. Await studies with quantitative synthesis and higher internal validity.
What is still missing
RCTs with adequate sample sizes, long follow-up, clinical caries outcomes (not merely bacterial counts), and a meta-analysis with formal heterogeneity and risk-of-bias assessment via AMSTAR-2 are needed.